Diagnostic HER2-binding radiopharmaceutical, [<sup>68</sup>Ga]Ga-ABY-025, for routine clinical use in breast cancer patients.
Irina Velikyan(Uppsala University), Jens Nørkær Sørensen(Technical University of Denmark), Philip Schweighöfer(Eckert & Ziegler (United States)), Henrik Lindman(Uppsala University), Johanna Seemann(Eckert & Ziegler (United States)), Joachim Feldwisch(Uppsala University), Fredrik Y. Frejd(Uppsala University)
PubMed
January 1, 2019
Cited by 38
Related Papers
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients
|Circulation|2019|526
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
|The Lancet|2000|343
Quantitative Assessment of Myocardial Perfusion in the Detection of Significant Coronary Artery Disease
|Journal of the American College of Cardiology|2014|324
Prospective of <sup>68</sup>Ga-Radiopharmaceutical Development
|Theranostics|2014|306